Comparison of risk-calculator and MRI and consecutive pathways as upfront stratification for prostate biopsy.
Daan J Reesink, Melline G M Schilham, Erik J R J van der Hoeven...
https://pubmed.ncbi.nlm.nih.gov/33090259/Actively Recruiting
Led by Norwegian University of Science and Technology · Updated on 2026-10-21
1016
Participants Needed
3
Research Sites
104 weeks
Total Duration
Prostate cancer is the most common non-skin cancer among men, often detected after an elevated prostate-specific antigen PSA blood test. Many men with elevated PSA do not have harmful cancer, leading to potentially unnecessary MRI scans and biopsies. This trial evaluates whether machine learning risk calculators can detect clinically significant prostate cancer as effectively as current MRI-based methods while reducing unnecessary procedures and anxiety. Participants will undergo risk stratification using the European Randomised Study of Screening for Prostate Cancer risk calculators to decide who needs further MRI scans and biopsies. This approach is compared to the current practice of performing MRI for all men with suspicious PSA levels. The study examines if risk stratification can safely reduce the number of MRIs and biopsies needed for diagnosis. Men in the study will be monitored during the initial diagnostic work-up, which lasts up to six weeks, with assessments including detection of clinically significant and insignificant prostate cancer and perilesional biopsy results. Follow-up will occur one year after inclusion to evaluate the number of biopsies and MRIs performed, quality of life related to biopsy decisions, and cost-effectiveness of the risk stratification approach.
CONDITIONS
Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer
P
Petter Davik, MD, PhD
J
Joakim S Lund, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Norwegian University of Science and Technology
Lead Sponsor
Norwegian Cancer Society
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - Up to 6 weeks
Participants undergo risk stratification using the European risk calculator to determine the need for MRI and prostate biopsy.
Visits as needed for MRI and biopsy procedures
Duration - 1 year
Participants are monitored for biopsy and MRI frequency, quality of life impacts, and cost-effectiveness one year after inclusion.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Daan J Reesink, Melline G M Schilham, Erik J R J van der Hoeven...
https://pubmed.ncbi.nlm.nih.gov/33090259/Bjørn Hofmann, Erik Skaaheim Haug, Eivind Richter Andersen...
https://pubmed.ncbi.nlm.nih.gov/36374190/Ian M Thompson, Donna Pauler Ankerst, Chen Chi...
https://pubmed.ncbi.nlm.nih.gov/16622122/Hiten D Patel, Sebastiaan Remmers, Jeffrey L Ellis...
https://pubmed.ncbi.nlm.nih.gov/38451522/Petter Davik, Sebastiaan Remmers, Mattijs Elschot...
https://pubmed.ncbi.nlm.nih.gov/35950035/Petter Davik, Sebastiaan Remmers, Mattijs Elschot...
https://pubmed.ncbi.nlm.nih.gov/37607322/Konstantius R V Straat, Marinus J Hagens, Leonor J Cools Paulino Pereira...
https://pubmed.ncbi.nlm.nih.gov/39483520/Petter Davik, Mattijs Elschot, Tone Frost Bathen...
https://pubmed.ncbi.nlm.nih.gov/38974460/Catherine Coyle, Eileen Morgan, Frances J Drummond...
https://pubmed.ncbi.nlm.nih.gov/28125998/Linda Sharp, Eileen Morgan, Frances J Drummond...
https://pubmed.ncbi.nlm.nih.gov/28766309/Norwegian University of Science and Technology
Lead Sponsor
Norwegian Cancer Society
Collaborating Sponsor